News | January 21, 2022
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The stability is led by healthy demand in the domestic and emerging markets
This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Subscribe To Our Newsletter & Stay Updated
